Ads
related to: bladder cancer in situ- Common Side Effects
See Possible Side Effects For A
Therapy For Metastatic Solid Tumors
- Data & Results
Explore Data To See If A
Therapy May Be An Option For You.
- Read About Biomarkers
What Should You Know About
IHC? Visit Site For Testing Info.
- Patient & Caregiver Site
Treatment For Certain People
With Metastatic Solid Tumors.
- Common Side Effects
Search results
Results From The WOW.Com Content Network
Exceptions include CIS of the colon (polyps), the bladder (preinvasive papillary cancer), or the breast (ductal carcinoma in situ or lobular carcinoma in situ). Many forms of CIS have a high probability of progression into cancer, [ 6 ] and therefore removal may be recommended; however, progression of CIS is known to be highly variable and not ...
Bladder cancer is much more common in men than women; around 1.1% of men and 0.27% of women develop bladder cancer. [2] This makes bladder cancer the sixth most common cancer in men, and the seventeenth in women. [57] When women are diagnosed with bladder cancer, they tend to have more advanced disease and consequently a poorer prognosis. [57]
A partial cystectomy is contraindicated in a form of bladder cancer called carcinoma in situ (CIS). Other contraindications for partial cystectomy include severely diminished bladder capacity or cancer in very close proximity to the bladder trigone, where the urethra and ureters connect to the bladder. [9]
Transitional cell carcinoma is a type of cancer that arises from the transitional epithelium, a tissue lining the inner surface of these hollow organs. [1] It typically occurs in the urothelium of the urinary system; in that case, it is also called urothelial carcinoma.
Efficacy was evaluated in QUILT-3.032 (NCT0302285), a single-arm, multicenter trial of 77 participants with Bacillus Calmette-Guérin-unresponsive, high-risk non-muscle invasive bladder cancer with carcinoma in situ with or without Ta/T1 papillary disease following transurethral resection. [6]
The safety and effectiveness of nadofaragene firadenovec was evaluated in a multicenter clinical study (Study CS-003 (NCT02773849)) that included 157 participants with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer, 98 of whom had BCG-unresponsive carcinoma in situ with or without papillary tumors and could be evaluated for response.